Patients undergoing immunotherapy for ccRCC still face significant obstacles due to the heterogeneity of CD8+ T cells, which roles in ccRCC immunization responses, metastasis, and prognosis have yet to be fully elucidated. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.